A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) - Louise Skau Rasmussen; Stine B. Winther; Inna M. Chen; Britta Weber; Lise Ventzel; Gabor Liposits; Julia Sidenius Johansen; Sönke Detlefsen; Ida Egendal; Susy Shim; Signe Christensen; Per Pfeiffer; et al. (BMC Cancer, 2023)